Shanghai RAAS Defends CDMO Plant Acquisition to Bolster Innovative Drug Capabilities

The notable point is the funding structure: Shanghai RAAS is explicitly tying its innovative-drug ambitions to blood-products cash flow rather than to a single large bet, a more conservative posture than the sector's usual narrative of aggressive pipeline spending. The acquired CDMO site functions as commercialization capacity, not just R&D, which suggests the company is positioning for late-stage manufacturing rather than early discovery. Whether that rolling, self-funded model can support the timeline innovative-drug development demands is the open question.